Markets
AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
COVID-19 vaccine makers turn to testing children
Health experts urge more research to help curb transmission and to reopen schools.
US Supreme Court takes up Goldman securities class action appeal
Goldman is appealing a decision allowing a class action accusing the bank of hiding conflicts of interest when creating risky subprime securities before the 2008 financial crisis.
How Pfizer delivered a COVID vaccine in record time: Crazy deadlines, a pushy CEO
Albert Bourla and his team overcame unproven science and manufacturing bottlenecks; ‘you’re asking for too much.’
Oracle moving from California to Texas, joins Tesla, Hewlett Packard
The tech giant is kissing California goodbye.
Disney leads Dow as S&P, Nasdaq slip
U.S. stocks post weekly losses.
Desktop Metal makes Wall Street debut
Trine Acquisition Corp. Chairman and CEO Leo Hindery and Desktop Metal CEO Ric Fulop provides insight into Desktop Metal and the company going public on the New York Stock Exchange.
How to prepare your investing strategy for 2021
BMO Capital Markets chief investment strategist Brian Belski and Laffer Tengler Investments chief investment officer Nancy Tengler look back on the markets in 2020 and share their tips on investing in 2021.
FDA's Pfizer COVID vaccine approval means Moderna's just days away
Moderna is next in line to win FDA approval for its COVID-19 vaccine.
Chinese auto giant Nio follows Tesla's lead to take advantage of surging stock prices
Chinese electric-car maker Nio Inc. is following U.S. rival Tesla Inc. by offering new shares to take advantage of its surging stock price.
Coronavirus vaccine, congressional gridlock to herald stock market 'nirvana'
The S&P 500 is poised to surge 20% next year as the U.S. economy strengthens and risks recede, according to J.P. Morgan.
2021’s first quarter will be 'very difficult' without stimulus: Economist
Moody's Analytics chief economist Mark Zandi shares his outlook for the economy and the need for a stimulus package.